Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

Table

SAFV-neutralizing antibodies in blood samples from humans of different ages and from different geographic regions*

Country

No. samples

Patient age†

Years collected

No. (%) samples

SAFV-2 pos‡

SAFV-3 pos‡

SAFV pos§

SAFV-2 pos + SAFV-3 neg

SAFV-2 neg + SAFV-3 pos

Netherlands

29

9 mo

2006–2007

15 (52)

4 (14)

15 (52)

11

0

Netherlands

26

24 mo

2006–2007

21 (81)

20 (77)

25 (96)

5

4

Netherlands

30

18–39 y

2004

30 (100)

29 (97)

30 (100)

1

0

Finland

30

2–2.5 y

1997–1998

10 (33)

21 (70)

24 (80)

3

14

Cameroon

29

5–15 y

1997

28 (97)

28 (97)

29 (100)

1

1

Indonesia

30

4–40 y

1997–1998

30 (100)

30 (100)

30 (100)

0

0

*SAFV, Saffold virus; pos, positive; neg, negative.†Samples were collected from patients at this age or within this age range.‡Titer >15.§Cumulative positive for antibodies against SAFV-2 and/or SAFV-3.

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.